Synergy Pharmaceuticals Reports Q3 Results

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has announced its financial results from the last quarter, ending on September 30, 2015.
According to the press release:

“The Synergy team continues to successfully execute on our key pipeline and corporate objectives,” said Gary S. Jacob, Chairman and CEO of Synergy. “Our strong year-to-date performance has resulted in a significant increase in value for our shareholders, enabling us to strengthen our balance sheet and financial position by reducing our debt by over 20%. We anticipate the next year will be marked by a number of value-enhancing opportunities, including our first planned NDA filing with plecanatide for CIC this coming January, pivotal results from our two ongoing phase 3 IBS-C trials, and a second NDA filing with plecanatide for IBS-C, all while building an agile commercial organization as we prepare for a potential U.S. launch with plecanatide in early 2017. The team remains focused on flawless execution across all areas of our business and we look forward to a very exciting 2016.”

Click here to read the full press release.